Skip to content

US · NRIX · BIOTECHNOLOGY

Nurix Therapeutics, Inc. (NRIX) intrinsic value and stock valuation

$12.85as of 2026-11-21 · Mkt cap 2.61B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nurix Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values NRIX with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from NRIX’s statements →

Nurix Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Brisbane, CA 94005 nurixtx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$84M+36.3% 5y CAGRd
20182025
Net income
-$-264.46M
20182025
Free cash flow
-$-263.47M
20182025
Total equity
$538.8M+13.2% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$84M$54.6M$77M$38.6M$29.8M
Operating income-$-285.67M-$-213.03M-$-155.06M-$-183.87M-$-117.89M
Net income-$-264.46M-$-193.57M-$-143.95M-$-180.36M-$-117.19M
EPSd-$-3.05M-$-2.88M-$-2.65M-$-3.71M-$-2.73M
Operating cash flow-$-249.47M-$-172.58M-$-81.36M-$-159.81M-$-84.36M
Capital expenditure-$-14M-$-9.27M-$-8.4M-$-12.24M-$-5.66M
Free cash flow-$-263.47M-$-181.86M-$-89.77M-$-172.05M-$-90.03M
Total assets$688.1M$669.3M$355.6M$416.8M$476.8M
Total debt$55.7M$28.3M$30.6M$12M$13M
Net debt-$-191.23M-$-81.69M-$-24.01M-$-52.51M-$-67.47M
Total equity$538.8M$527M$200.5M$303.7M$342.3M
Cash and short-term investments$592.9M$609.6M$287.9M$309.1M$295.7M
Income statement
20252024202320222021
Revenue$84M$54.6M$77M$38.6M$29.8M
Cost of revenue$18.9M$221.6M$189.2M$184.5M$116.4M
Gross profit$65.1M-$-167.08M-$-112.16M-$-145.87M-$-86.68M
Research and development expenses$308.2M$221.6M$189.2M$184.5M$116.4M
Selling, general and administrative expenses$52.7M$45.9M$42.9M$38M$31.2M
Other expenses-$-10.12M-$-221.63M-$-189.15M-$-184.5M-$-116.43M
Operating expenses$350.8M$45.9M$42.9M$38M$31.2M
Cost and expenses$369.7M$267.6M$232.1M$222.5M$147.6M
Interest income$22M$19.7M$11.1M$3.51M$820K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$18.9M$8.02M$6.13M$4.15M$1.99M
Ebitda-$-244.84M-$-185.28M-$-137.81M-$-176.21M-$-115.07M
Operating income-$-285.67M-$-213.03M-$-155.06M-$-183.87M-$-117.89M
Total other income/expenses, net$22M$19.7M$11.1M$3.51M$820K
Income before tax-$-263.7M-$-193.3M-$-143.95M-$-180.36M-$-117.06M
Income tax expense$760K$270K$0.00$0.00$130K
Net income-$-264.46M-$-193.57M-$-143.95M-$-180.36M-$-117.19M
Weighted average shares outstanding$86.7M$67.1M$54.3M$48.6M$42.9M
Weighted average diluted shares outstanding$86.7M$67.1M$54.3M$48.6M$42.9M
Balance sheet
20252024202320222021
Cash and short-term investments$592.9M$609.6M$287.9M$309.1M$295.7M
Net receivables$0.00$1.5M$800K$1.1M$6.2M
Inventory$0.00$0.00$0.00-$-1.1M$0.00
Total current assets$606.8M$619.4M$295.5M$318.5M$311.1M
Property, plant and equipment, net$73M$45.9M$48M$29.5M$25.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$7.42M$63.9M$137.5M
Total non-current assets$81.3M$50M$60.1M$98.3M$165.7M
Total assets$688.1M$669.3M$355.6M$416.8M$476.8M
Accounts payable$11.2M$11.5M$6.4M$5.06M$6.65M
Short-term debt$2.82M$8.01M$7.49M$5.53M$3.85M
Deferred revenue$17.6M$38.4M$48.1M$37.6M$41.2M
Total current liabilities$86.5M$95.9M$87M$70.7M$66.3M
Long-term debt$52.9M$20.3M$23.1M$6.43M$9.19M
Deferred revenue, non-current$10M$26.2M$45M$36M$59M
Total non-current liabilities$62.9M$46.5M$68.2M$42.4M$68.2M
Capital lease obligations$55.7M$28.3M$23.1M$6.43M$9.19M
Total liabilities$149.4M$142.4M$155.1M$113.1M$134.5M
Common stock$100K$80K$50K$50K$40K
Retained earnings-$-1B-$-738.77M-$-545.2M-$-401.25M-$-220.89M
Accumulated other comprehensive income (loss)$100K$150K-$-660K-$-4.32M-$-610K
Total equity$538.8M$527M$200.5M$303.7M$342.3M
Total investments$346M$499.6M$240.7M$308.6M$352.4M
Total debt$55.7M$28.3M$30.6M$12M$13M
Net debt-$-191.23M-$-81.69M-$-24.01M-$-52.51M-$-67.47M
Cash flow statement
20252024202320222021
Net income-$-264.46M-$-193.57M-$-143.95M-$-180.36M-$-117.19M
Depreciation and amortization$18.9M$16.4M$13.7M$10.8M$6.08M
Stock-based compensation$38M$33.9M$33.7M$28.1M$15.8M
Change in working capital-$-31.6M-$-18.4M$20.1M-$-19.02M$9.11M
Accounts receivable$0.00$0.00$0.00$6M-$-6M
Inventory$0.00$0.00$0.00$0.00$6.77M
Accounts payable-$-630K$5.21M$1.61M$90K$1.59M
Net cash provided by operating activities-$-249.47M-$-172.58M-$-81.36M-$-159.81M-$-84.36M
Investments in property, plant and equipment-$-14M-$-9.27M-$-8.4M-$-12.24M-$-5.66M
Acquisitions, net$0.00$0.00$0.00-$-39.44M$102.6M
Net cash used for investing activities$147.9M-$-257.71M$68.3M$27.2M-$-108.25M
Common stock issued$238.6M$478.5M$3.22M$19.4M$150.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$238.6M$485.7M$3.22M$117.2M$153.9M
Net change in cash$137M$55.4M-$-9.85M-$-15.42M-$-38.73M
Cash at end of period$247.9M$110.9M$55.5M$65.4M$80.8M
Operating cash flow-$-249.47M-$-172.58M-$-81.36M-$-159.81M-$-84.36M
Capital expenditure-$-14M-$-9.27M-$-8.4M-$-12.24M-$-5.66M
Free cash flow-$-263.47M-$-181.86M-$-89.77M-$-172.05M-$-90.03M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nurix Therapeutics, Inc.

        Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

        CEO
        Arthur T. Sands
        Employees
        317
        Beta
        1.80

        Explore

        Frequently asked questions

        What is the intrinsic value of Nurix Therapeutics, Inc. (NRIX)?

        Nurix Therapeutics, Inc. (NRIX) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NRIX undervalued?

        NRIX trades at a price of $12.85 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.